The Effect of LipoCol Forte® Capsules on the Pharmacokinetics of Nifedipine After Administering Single-dose Combination to Healthy Subjects

• Status: Completed
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the study is to evaluate the effect of LipoCol Forte® Capsules on the pharmacokinetics of nifedipine after administering single-dose combination to healthy subjects using a 2x2 crossover design.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Taipei Medical University WanFang Hospital
• Treatments: Nifedipine

Criteria

Inclusion Criteria:

1. Subjects must be at the age of 20-40 years old and in good health on the basis of medical history, physical examination, electrocardiogram, chest X-ray, and routine laboratory evaluations.

2. Vital signs (after 3 minutes resting in a upright position) which are within the following ranges:Ear body temperature between 35.0-37.5 degree celsius (°C). Systolic blood pressure, 90-140 millimeters of mercury (mm Hg). Diastolic blood pressure, 50-90 millimeters of mercury (mm Hg). Pulse rate, 50-90 beats per minute (bpm). Fasting blood glucose, < 110 milligrams per deciliter (mg/dL).

3. Body weight must be above 50 kilograms (kg) and within -20 to +20% of ideal body weight.

4. Able to sign informed consent prior to study.

5. Able to communicate well with the investigator and comply with the requirements of the study.

Exclusion Criteria:

1. Use of any prescription medication within 14 days prior to dosing.

2. Use of over-the-counter medications or vitamins within 14 days prior to dosing.

3. Significant illness within 2 weeks prior to dosing.

4. Participation in any clinical investigation within 2 months prior to dosing or longer than required by local regulation.

5. Donate or loss more than 500 milliliter(mL) of blood within 3 months prior to dosing.

6. Presence of cardiovascular disease.

7. Presence of gastrointestinal disease.

8. Presence of asthma or lung disease.

9. Presence of liver disease, hepatitis B, hepatitis C or liver injury as indicated by an abnormal liver function profile.

10. Presence of impaired renal function.

11. Presence of neurological disease.

12. Presence of psychiatrical disease.

13. Subject is known for HIV infected.

14. A known hypersensitivity to nifedipine, lovastatin and Chinese Red Yeast Rice or their analogs.

15. History of drug or alcohol abuse within 12 months prior to dosing.

16. Permanent confinement to an institution.

17. Individuals are judged by the investigator or pharmacokineticist to be undesirable as subjects for other reasons.